Safety, pharmacokinetics and pharmacodynamics of SBT‐020 in patients with early stage Huntington's disease, a 2‐part study

AIMS: Huntington's disease (HD) is a neurodegenerative disease with cognitive, motor and psychiatric symptoms. Toxic accumulation of misfolded mutant huntingtin protein induces mitochondrial dysfunction, leading to a bioenergetic insufficiency in neuronal and muscle cells. We evaluated the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: van Diemen, Marcus P.J., Hart, Ellen P., Abbruscato, Anthony, Mead, Liz, van Beelen, Ilse, Bergheanu, Sandrin C., Hameeteman, Pieter W., Coppen, Emma, Winder, Jessica Y., Moerland, Matthijs, Kan, Hermien, van der Grond, Jeroen, Webb, Andrew, Roos, Raymund A.C., Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247328/
https://www.ncbi.nlm.nih.gov/pubmed/33197078
http://dx.doi.org/10.1111/bcp.14656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247328/
https://www.ncbi.nlm.nih.gov/pubmed/33197078
http://dx.doi.org/10.1111/bcp.14656

Ejemplares similares